Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The world is witnessing a diabetes pandemic. It is expected that the estimated number of patients with diabetes of 150 million
in the late 1990s will reach 300 million by 2025. In the late 1970s and early 1980s, diabetes was not considered a commonly
encountered medical diagnosis in Saudi Arabia even in high-risk groups, and among the male Saudi population the prevalence
of diabetes was not different from other parts of the world. However, this seems to have changed dramatically in the last two
decades, as the prevalence of diabetes in Saudi Arabia is now one of the highest in the world. Diabetes mellitus, especially type
2 is a polygenic disorder and the high consanguinity rate among Saudis may be playing a significant role in its prevalence. Also,
obesity is a well-known and strong risk factor for diabetes, especially in high-risk population. National epidemiological survey by
Al- Nozha et al (2004) showed the overall prevalence of type 2 diabetes mellitus is 27.3%.
Insulin resistance is an important feature of type 2 diabetes. It is being increasingly recognized that low testosterone levels in
men are associated with reduced insulin sensitivity and type 2 diabetes. Furthermore, male hypogonadism is a clinical condition
that affects a significant number of men in the United States and can involve up to 50% of men diagnosed with type 2 diabetes.
Older age and obesity may be risk factors, as both are associated with type 2 diabetes and both decrease testosterone levels. Sex
hormone-binding globulin (SHBG), the major serum carrier protein for testosterone, also may have an impact. SHBG levels fall
with obesity and increase with aging. Some studies indicate lower SHBG levels in type 2 diabetes. However, free testosterone
levels fall with increasing age and obesity, rendering many type 2 diabetic patients testosterone deficient. Recent work shows
a high prevalence of low testosterone and inappropriately low LH and FSH concentrations in type 2 diabetes. This syndrome
of hypogonadotrophic hypogonadism is associated with obesity, and other features of the metabolic syndrome (obesity and
overweight, hypertension and hyperlipidemia) in patients with type 2 diabetes.However, the duration of diabetes or HbA1c were
not related to hypogonadotrophic hypogonadism. Furthermore, recent data show that hypogonadotrophic hypogonadism is also
observed frequently in patients with the metabolic syndrome without diabetes but is not associated with type 1 diabetes. Thus,
hypogonadotrophic hypogonadism appears to be related to the two major conditions associated with insulin resistance: type 2
diabetes and the metabolic syndrome. CRP concentrations have been shown to be elevated in patients with hypogonadotrophic
hypogonadism and are inversely related to plasma testosterone concentrations. This is of interest since inflammatory mechanisms
may have a cardinal role in the pathogenesis of insulin resistance. Hypogonadotrophic hypogonadism may be the result of insulin
resistance at the level of the GnRH secreting neuron. Low testosterone concentrations in type 2 diabetic men have also been related
to a significantly lower hematocrit and thus to an increased frequency of mild anemia. Low testosterone concentrations are also
related to an increase in total and regional adiposity, and to lower bone density.
Erectile dysfunction (ED) is a common and distressing complication of diabetes. Large differences in the reported prevalence
of ED from 35% to 90% among diabetic men could be due to differences in methodology and population characteristics. Advancing
age, duration of diabetes, poor glycaemic control, hypertension, hyperlipidemia, sedentary lifestyle, smoking, and presence of
other diabetic complications have been shown to be associated with ED in diabetic patients in cross-sectional studies. ED in
diabetic patients is multifactorial in aetiology and is more severe and more resistant to treatment compared with non-diabetics.
There are no studies demonstrating the prevalence of hypogonadism in type 2 diabetic patients in Saudi Arabia .The aims
of this study were to find out the prevalence of hypogonadism in Saudi type 2 diabetic patients by measuring total & bioavailable
testosterone levels and by calculating the free testosterone levels. Moreover, the study also aimed to identify the effect of metabolic
syndrome and other factors on testosterone levels and thus to highlight the importance of evaluating the gonadal system of type 2
diabetic patient visiting the clinic.
Testosterone levels are frequently low in Saudi men with type 2 diabetes, and the majority of these men have
symptoms of hypogonadism. Obesity is associated with low testosterone levels in diabetic men.
Asim Hassan is a graduate from King Edward Medical College, Lahore, Pakistan. He has a MRCP (UK) and SCE (UK) (Speciality Certificate
Examination) from the royal college of Physicians of United Kingdom. Currently he is working as a Consultant Endocrinologist & Assistant Professor
in University Diabetes Center, King Abdul Aziz University Hospital, King Saud University Riyadh Saudi Arabia
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals